靶向PLA2R的嵌合自身抗体受体T细胞治疗膜性肾病的临床前评估
该临床前研究构建了靶向PLA2R免疫优势表位的嵌合自身抗体受体T细胞(CAART),在体外和Nalm-6异种移植小鼠模型中验证其特异性清除抗PLA2R B细胞并吸附血浆抗PLA2R抗体的能力,且未观察到显著脱靶毒性,为PLA2R膜性肾病的抗原特异性B细胞清除治疗提供了概念验证。
要点
- C17与C178-CAART在体外特异性杀伤靶向CysR、CTLD1、CTLD7表位的抗PLA2R B细胞系。
- 与患者原代B细胞或血浆共孵育后,C17和C178-CAART显著减少抗PLA2R B细胞并吸附69-97%血浆抗PLA2R抗体反应性。
- 体内实验显示C17和C178-CAART显著减少靶细胞生长,且无显著脱靶结合,支持进一步临床可行性研究。
核心结论
- PLA2R-CAART(靶向PLA2R的嵌合自身抗体受体T细胞)在临床前模型中可实现抗原特异性B细胞清除并吸附致病性抗PLA2R抗体,为PLA2R膜性肾病提供治疗概念验证。
研究设计与样本
- 临床前研究:通过慢病毒转导构建PLA2R-CAART,体外评估细胞毒性与特异性,并在Nalm-6异种移植小鼠模型及人膜蛋白组阵列中进行体内外验证。
主要发现
- C17和C178-CAART(涵盖CysR、CTLD1、CTLD7,含或不含CTLD8结构域)在原代T细胞上成功表达,并对靶向CysR、CTLD1、CTLD7表位的抗PLA2R B细胞系表现出特异性体外细胞毒性。
- 与患者原代B细胞或血浆共孵育时,C17和C178-CAART显著减少抗PLA2R B细胞,并吸附69-97%的血浆抗PLA2R抗体反应性。
- 在Nalm-6异种移植模型中,C17和C178-CAART治疗显著减少靶细胞生长,其中C17-CAART细胞毒性略高但持续;体内病理分析和高通量膜蛋白组阵列未显示显著脱靶结合。
关键数值与推荐
- C17和C178-CAART吸附69-97%血浆抗PLA2R抗体反应性(对象:PLA2R膜性肾病患者血浆,条件:共孵育)。
临床怎么用
- 目前仅为临床前概念验证,尚不能用于临床实践;需进一步研究确定PLA2R-CAART治疗PLA2R膜性肾病的临床可行性。
局限性
- 研究为临床前阶段,需额外研究确定临床可行性;动物模型为异种移植模型,结果外推至患者需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Phospholipase A2 receptor (PLA2R)-associated membranous nephropathy (MN) is a leading cause of nephrotic syndrome in adults, driven by autoantibodies that target PLA2R on kidney podocytes. Antibody-based therapy with rituximab induces broad B-cell depletion but is associated with risks of serious infection and reduced efficacy in patients with high proteinuria. Here, we determined the feasibility of developing chimeric autoantibody receptor T-cell (CAART) therapy for PLA2R-specific B-cell depletion in PLA2R MN. METHODS: PLA2R-CAART was produced by T-cell lentiviral transduction. In vitro cytotoxicity and specificity were evaluated against B-cell lines targeting PLA2R immunodominant epitopes and primary PLA2R MN B cells. Adsorption of PLA2R MN IgG was evaluated to determine the extent of pathogenic autoantibody targeting by candidate PLA2R-CAART designs. Specific cytotoxicity, engraftment capability, and off-target toxicity were evaluated in a xenografted anti-PLA2R Nalm-6 preclinical mouse model, with additional toxicology screening by human membrane proteome arrays. RESULTS: We engineered CAARTs targeting key PLA2R epitopes to selectively deplete autoreactive B cells. C17- and C178-CAART (encompassing CysR, CTLD1, and CTLD7, with/without CTLD8 domains) were successfully expressed on primary T cells and demonstrated specific in vitro cytotoxicity against anti-PLA2R B-cell lines targeting CysR, CTLD1, and CTLD7 epitopes. In co-incubation assays with primary B cells or plasma from patients with MN, C17- and C178-CAART significantly reduced anti-PLA2R B cells and adsorbed 69-97% of plasma anti-PLA2R antibody reactivity. In vivo, C17- and C178-CAART treatment in the Nalm-6 xenograft model resulted in significant reduction in target cell outgrowth with C17-CAART showing slight but consistently increased cytotoxic activity. Specificity testing through comprehensive in vivo pathologic analysis and a high-throughput membrane proteome array analysis showed no significant off-target binding for either C17- or C178-CAART. CONCLUSIONS: Our findings establish preclinical proof-of-concept for the therapeutic potential of antigen-specific B-cell depletion by PLA2R-CAART. Additional studies are required to determine clinical feasibility of PLA2R-CAART for PLA2R MN therapy.
引用
- Altun B, Zhao G, Wang B, et al. Preclinical evaluation of antigen-specific B-cell depletion for phospholipase A2 receptor membranous nephropathy with chimeric autoantibody receptor T cells. Kidney Int. 2025. PMID: 41177511. doi:10.1016/j.kint.2025.09.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。